EU to test disputed incentive scheme to develop novel antibiotics
The revamp of the bloc’s regulatory framework for pharmaceuticals, presented by the European Commission on Wednesday (26 April), features a new and somewhat controversial system of incentives to promote the development of new antimicrobials.
The development of novel antibiotics is seen as a solution to this ‘silent pandemic’ that claims more than 35,000 lives per year in Europe.
In its reform of the EU pharma rules, the Commission proposed a 15-year trial of a ‘transferable data exclusivity voucher scheme’ for novel antibiotics to incentivise their developers.
In practice, the voucher will grant an additional year of regulatory data protection to the developer of the novel antibiotics, which can either be used for one of its own products or sold to another marketing authorisation holder.
OUR UNDERWRITERS
Unrestricted financial support by:
 |
Antimicrobial Resistance Fighter Coalition |
 |
Bangalore Bioinnovation Centre |
 |
Evotec |
 |
JSS University |
 |
INTERNATIONAL FEDERATION PHARMACEUTICAL MANUFACTURERS & ASSOCIATIONS |
Global Ambassador Network
Welcome at the AMR Insights Ambassador Network!
The AMR Insights Ambassador Network is a growing, distinctive group of professionals who stand out for their commitment, willingness to cooperate and open attitude to combat Antimicrobial resistance (AMR).
